Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STACY R SMITH

Allopathic & Osteopathic Physicians Dermatology

NPI
1780651760
CMS profile
172031
Location
ENCINITAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$205,320.69

167 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $100,379.71 79
Lilly USA, LLC $68,029.54 65
Janssen Scientific Affairs, LLC $26,366.66 14
Janssen Biotech, Inc. $7,191.69 6
Incyte Corporation $3,334.22 2
Allergan, Inc. $18.87 1

Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STACY R SMITH

NPI 1780651760 · CMS profile ID 172031

Allopathic & Osteopathic Physicians / Dermatology

ENCINITAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780651760?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STACY R SMITH, NPI 1780651760, CMS profile ID 172031. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780651760?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). STACY R SMITH, NPI 1780651760, CMS profile ID 172031. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780651760?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
STACY R SMITH, NPI 1780651760, CMS profile ID 172031, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–167 of 167 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1780651760?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

167 matching records · $205,320.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 167 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–167 of 167.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $349.9003/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631273 CMS
Allergan, Inc. $18.8703/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 889987089 CMS
ABBVIE INC. $2,175.0003/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631261 CMS
Incyte Corporation $9.2203/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942996043 CMS
ABBVIE INC. $2,175.0002/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631259 CMS
Lilly USA, LLC $3,000.0002/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918305967 CMS
ABBVIE INC. $2,175.0002/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631257 CMS
ABBVIE INC. $2,175.0002/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631255 CMS
ABBVIE INC. $2,175.0002/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631251 CMS
ABBVIE INC. $2,175.0002/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631253 CMS
ABBVIE INC. $2,175.0002/03/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631249 CMS
ABBVIE INC. $2,175.0001/24/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631247 CMS
Janssen Scientific Affairs, LLC $3,575.0001/20/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887180895 CMS
ABBVIE INC. $6.9601/13/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631239 CMS
ABBVIE INC. $6.9601/13/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631241 CMS
ABBVIE INC. $6.9601/13/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631243 CMS
ABBVIE INC. $6.9601/13/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891631245 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $238,543.49 189
PY2020 $106,979.79 62
PY2021 $75,437.87 46
PY2022 $205,320.69 167
PY2023 $167,570.08 125
PY2024 $108,763.99 65
PY2025 $90,861.71 38

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $597,549.12 86
PY2024 Recipient $20,888.46 6
PY2024 Principal investigator $853,139.17 98
PY2023 Recipient $67,948.50 9
PY2023 Principal investigator $984,151.62 101
PY2022 Recipient $99,391.75 10
PY2022 Principal investigator $524,078.59 122
PY2021 Recipient $7,507.46 4
PY2021 Principal investigator $713,400.61 97
PY2020 Recipient $30,023.02 10
PY2020 Principal investigator $1,292,540.76 139
PY2019 Recipient $99,694.50 15
PY2019 Principal investigator $1,940,238.54 176

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $16,158.80 12/31/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Inst
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NON SEGMENTAL VITILIGO No dispute reported 06/30/2026 1228732865
Principal investigator 1 PFIZER INC. $3,113.60 12/25/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228733715
Principal investigator 1 PFIZER INC. $2,320.73 12/24/2025 Non-covered Recipient Entity
Stacy R Smith MD
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228719993
Principal investigator 1 Janssen Research & Development, LLC $2,539.00 12/22/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175369896
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,760.30 12/18/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434752
Principal investigator 1 PFIZER INC. $4,641.46 12/17/2025 Non-covered Recipient Entity
Stacy R Smith MD
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228746246
Principal investigator 1 Janssen Research & Development, LLC $2,493.00 12/15/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175369929
Principal investigator 1 PFIZER INC. $5,537.55 12/11/2025 Non-covered Recipient Entity
Stacy R Smith MD
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228720471
Principal investigator 1 PFIZER INC. $3,113.60 12/11/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228725796
Principal investigator 1 Eli Lilly and Company $7,500.00 12/01/2025 Non-covered Recipient Entity
STACY SMITH MD APC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187889862
Principal investigator 1 PFIZER INC. $17,094.83 11/26/2025 Non-covered Recipient Entity
Stacy R Smith MD
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228738259
Principal investigator 1 PFIZER INC. $3,113.60 11/25/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228738411
Principal investigator 1 PFIZER INC. $5,537.55 11/13/2025 Non-covered Recipient Entity
Stacy R Smith MD
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228737203
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,760.30 11/13/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434747
Principal investigator 1 PFIZER INC. $3,113.60 11/04/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228739151
Principal investigator 1 Janssen Research & Development, LLC $2,539.00 10/31/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175369954
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
California Dermatology And Clinical Research Institute
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235998480
Principal investigator 1 Janssen Research & Development, LLC $4,986.00 10/27/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175369913
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,621.93 10/23/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434741
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,500.00 10/22/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246434725
Principal investigator 1 PFIZER INC. $3,113.60 10/21/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228730646
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,000.00 10/14/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434743
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,074.20 10/13/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis No dispute reported 06/30/2026 1246434729
Principal investigator 1 Eli Lilly and Company $21,975.00 10/10/2025 Non-covered Recipient Entity
STACY SMITH MD APC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187890294
Principal investigator 1 Eli Lilly and Company $2,945.86 09/09/2025 Non-covered Recipient Entity
STACY SMITH MD APC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187890070
Principal investigator 1 Janssen Research & Development, LLC $3,030.00 09/01/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175370039
Principal investigator 1 PFIZER INC. $7,551.60 08/30/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228765675
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,500.00 08/27/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434733
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,075.00 08/27/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis No dispute reported 06/30/2026 1246434736
Principal investigator 1 PFIZER INC. $2,219.00 08/05/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766469
Principal investigator 1 Janssen Research & Development, LLC $1,897.00 08/04/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175369993
Principal investigator 1 Janssen Research & Development, LLC $7,545.00 07/28/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175369942
Principal investigator 1 PFIZER INC. $5,332.60 07/16/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228765269
Principal investigator 1 Janssen Research & Development, LLC $1,897.00 07/10/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175370008
Principal investigator 1 PFIZER INC. $1,559.60 06/26/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228776581
Principal investigator 1 PFIZER INC. $22,000.00 06/26/2025 Non-covered Recipient Entity
Stacy R Smith MD
A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA No dispute reported 06/30/2026 1228792728
Principal investigator 1 Eli Lilly and Company $2,000.00 06/05/2025 Non-covered Recipient Entity
STACY SMITH MD APC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187890292
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169624
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169665
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169684
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169694
Principal investigator 1 Janssen Research & Development, LLC $3,068.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169716
Principal investigator 1 Janssen Research & Development, LLC $2,518.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169749
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169765
Principal investigator 1 Janssen Research & Development, LLC $1,974.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169780
Principal investigator 1 Janssen Research & Development, LLC $205.00 06/04/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169787
Principal investigator 1 Janssen Research & Development, LLC $1,722.00 05/28/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169606
Principal investigator 1 Janssen Research & Development, LLC $254.00 05/28/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169649
Principal investigator 1 Janssen Research & Development, LLC $810.00 05/28/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169657
Principal investigator 1 Janssen Research & Development, LLC $156.00 05/28/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169772
Principal investigator 1 Janssen Research & Development, LLC $5,682.00 05/26/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175369889
Principal investigator 1 PFIZER INC. $2,219.00 05/23/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228723656
Principal investigator 1 Janssen Research & Development, LLC $4,591.00 05/21/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169710
Principal investigator 1 Janssen Research & Development, LLC $10,212.00 05/15/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169616
Principal investigator 1 PFIZER INC. $6,232.80 05/14/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228782406
Principal investigator 1 Janssen Research & Development, LLC $5,918.00 05/09/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175369920
Principal investigator 1 PFIZER INC. $5,997.60 05/06/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228781893
Principal investigator 1 Janssen Research & Development, LLC $6,808.00 04/28/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169677
Principal investigator 1 Janssen Research & Development, LLC $5,386.00 04/28/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175370019
Principal investigator 1 Amgen Inc. $82,364.00 04/24/2025 Non-covered Recipient Entity
STACY R SMITH MD APC CALIFORNIA DERMATOLOGY & CLINICAL RESEARCH INSTITUTE
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246648666
Principal investigator 1 Amgen Inc. $4,000.00 03/25/2025 Non-covered Recipient Entity
CALIFORNIA DERMATOLOGY AND CLINICAL RESEARCH INSTITUTE
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) No dispute reported 06/30/2026 1246639847
Principal investigator 1 Eli Lilly and Company $1,939.39 03/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH INSTITUTE LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187883084
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/24/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169702
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 03/24/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169756
Principal investigator 1 Janssen Research & Development, LLC $2,693.00 03/24/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175369950
Principal investigator 1 Janssen Research & Development, LLC $10,500.00 03/19/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169597
Principal investigator 1 Janssen Research & Development, LLC $8,044.00 03/19/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175169734
Principal investigator 1 PFIZER INC. $1,454.60 03/14/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228796856
Principal investigator 1 Janssen Research & Development, LLC $10,378.00 03/06/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175369964
Principal investigator 1 Eli Lilly and Company $108.73 03/04/2025 Non-covered Recipient Entity
STACY SMITH MD APC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187890072
Principal investigator 1 PFIZER INC. $4,202.80 03/04/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228778483
Principal investigator 1 Janssen Research & Development, LLC $11,262.00 03/03/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169639
Principal investigator 1 Janssen Research & Development, LLC $10,324.00 03/03/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175370027
Principal investigator 1 Eli Lilly and Company $1,658.00 02/18/2025 Non-covered Recipient Entity
STACY SMITH MD APC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187890074
Principal investigator 1 Janssen Research & Development, LLC $11,592.00 02/12/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169630
Principal investigator 1 Janssen Research & Development, LLC $1,788.00 02/12/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169741
Principal investigator 1 Janssen Research & Development, LLC $3,880.00 01/31/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175369978
Principal investigator 1 Amgen Inc. $44,739.60 01/30/2025 Non-covered Recipient Entity
CALIFORNIA DERMATOLOGY AND CLINICAL RESEARCH INSTITUTE
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639845
Principal investigator 1 Janssen Research & Development, LLC $11,019.00 01/27/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175369934
Principal investigator 1 PFIZER INC. $14,637.00 01/24/2025 Non-covered Recipient Entity
California Dermatology Clinical Research Institute
A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSEUP TITRATION MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY EFFICACY AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228798754
Principal investigator 1 Janssen Research & Development, LLC $1,332.00 01/20/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175369906
Principal investigator 1 Janssen Research & Development, LLC $414.00 01/20/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175369985
Principal investigator 1 Janssen Research & Development, LLC $756.00 01/20/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175370001
Principal investigator 1 Janssen Research & Development, LLC $3,446.00 01/17/2025 Non-covered Recipient Entity
STACY R SMITH MD APC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175369970
Principal investigator 1 Janssen Research & Development, LLC $7,508.00 01/16/2025 Non-covered Recipient Entity
California Derm and Clinic Rsrch Inst
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) No dispute reported 06/30/2026 1175169727
Principal investigator 1 Eli Lilly and Company $76,574.00 01/13/2025 Non-covered Recipient Entity
STACY SMITH MD APC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187890296